Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 9:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 202 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Buffered Injection Clear all
Completed Phase 3 Interventional

Study of the Long-Term Safety of Pramlintide in Subjects With Type 1 Diabetes Mellitus

NCT00107107
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
pramlintide acetate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
25
States / cities
Tempe, Arizona • Concord, California • Fresno, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2015 · Synced Oct 22, 2026, 9:32 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis

NCT03259334
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Ontamalimab, Placebo
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
16 Years to 80 Years
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
38
States / cities
Little Rock, Arkansas • Lancaster, California • Rialto, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 22, 2026, 9:32 PM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

J-Tip® Jet Injection of 1% Buffered Lidocaine or Saline Versus 4% Lidocaine Cream Before Venipuncture or IV Insertion

NCT00924963
View directory record Official record
Conditions
Pain
Interventions
J-Tip jet injector, Jet injection saline, lidocaine cream
Device · Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
7 Years to 21 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Liberty Township, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 21, 2020 · Synced Oct 22, 2026, 9:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First-in-human Study of 10-1074-LS Alone and in Combination With 3BNC117-LS

NCT03554408
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
10-1074-LS, 3BNC117-LS
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 65 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Oct 22, 2026, 9:32 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study in Healthy Adults to Evaluate the Safety and Immunogenicity of Different Doses of JNJ-63871860

NCT02546960
View directory record Official record
Conditions
Healthy
Interventions
ExPEC4V (4 : 4 : 4 : 4), ExPEC4V (4 : 4 : 4 : 8), ExPEC4V (8 : 8 : 8 : 8), ExPEC4V (8 : 8 : 8 : 16), ExPEC4V (16 : 16 : 16 : 16), Placebo
Biological · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
848 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
17
States / cities
Mesa, Arizona • Hollywood, Florida • Leesburg, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2020 · Synced Oct 22, 2026, 9:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

RHA® 4 With New Anesthetic - Nasolabial Folds

NCT04087395
View directory record Official record
Conditions
Aging, Pain
Interventions
RHA®4 with new anesthetic agent, RHA®4-Lidocaine
Device
Lead sponsor
Teoxane SA
Industry
Eligibility
22 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
3
States / cities
Beverly Hills, California • Coral Gables, Florida • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 24, 2022 · Synced Oct 22, 2026, 9:32 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Long-term Follow-up Study to Evaluate Safety and Immunogenicity of CHIKV VLP Single or Booster Vaccination

NCT06007183
View directory record Official record
Conditions
Chikungunya Virus Infection
Interventions
CHIKV VLP vaccine booster, Placebo booster
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
12 Years and older
Enrollment
715 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
24
States / cities
Mobile, Alabama • Tempe, Arizona • Melbourne, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 22, 2026, 9:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad35.RSV.FA2 Regimens Boosted With Ad26.RSV.FA2 in Healthy Adult Participants

NCT02440035
View directory record Official record
Conditions
Healthy Participants
Interventions
Ad35.RSV.FA2, Ad26.RSV.FA2, Placebo
Biological · Drug
Lead sponsor
Crucell Holland BV
Industry
Eligibility
18 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Oct 22, 2026, 9:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Study of the Efficacy and Safety of EUFLEXXA™ for Treatment of Painful Osteoarthritis of the Knee

NCT00379236
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
EUFLEXXA™, placebo
Device
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
588 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 28, 2011 · Synced Oct 22, 2026, 9:32 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS)

NCT00587990
View directory record Official record
Conditions
Stem Cell Transplantation, Ventricular Dysfunction, Left
Interventions
Lower dose mesenchymal stem cell (MSC) injection, Placebo, Higher dose MSC injection
Biological · Genetic
Lead sponsor
Joshua M Hare
Other
Eligibility
21 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Miami, Florida • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Oct 22, 2026, 9:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Salmonella Conjugates CVD 2000: Study of Responses to Vaccination With Trivalent Salmonella Conjugate Vaccine to Prevent Invasive Salmonella Disease

NCT05525546
View directory record Official record
Conditions
Risk Reduction
Interventions
Trivalent Salmonella Conjugate Vaccine (TSCV) Full-Strength Formulation, Trivalent Salmonella Conjugate Vaccine (TSCV) Half-Strength Formulation, Trivalent Salmonella Conjugate Vaccine (TSCV) Dilutional Half-Strength Formulation, Placebo
Biological · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 49 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 22, 2026, 9:32 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Study of Healthy Aging and Physical Function With Elamipretide

NCT07275424
View directory record Official record
Conditions
Aging, Healthy
Interventions
Elamipretide will be supplied as a sterile 5.0 mL single-patient, multi-dose glass vial containing 3.75 mL of elamipretide solution (elamipretide [80 mg/mL], phosphate buffer, and benzyl alcohol)
Drug
Lead sponsor
David Marcinek
Other
Eligibility
65 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Oct 22, 2026, 9:32 PM EDT
Terminated Not applicable Interventional Results available

Durolane Versus Phosphate Buffered Saline (PBS) in Knee Osteoarthritis

NCT01753830
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Durolane, PBS
Device
Lead sponsor
Galderma R&D
Industry
Eligibility
40 Years to 80 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
25
States / cities
Anniston, Alabama • Mobile, Alabama • Phoenix, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2022 · Synced Oct 22, 2026, 9:32 PM EDT
Withdrawn Phase 1Phase 2 Interventional

A Study to Investigate the Safety and Efficacy of a Novel Furosemide Regimen

NCT02721511
View directory record Official record
Conditions
Acute Decompensated Heart Failure
Interventions
Furosemide Injection Solution 8mg/mL
Drug
Lead sponsor
Todd M Koelling, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 24, 2017 · Synced Oct 22, 2026, 9:32 PM EDT
Completed Phase 1Phase 2 Interventional

In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy

NCT01976585
View directory record Official record
Conditions
Low-Grade B-cell Lymphoma
Interventions
rhuFlt3L/CDX-301, Poly-ICLC
Drug
Lead sponsor
Joshua Brody
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 22, 2022 · Synced Oct 22, 2026, 9:32 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Clinical Outcomes Mandible: Buffered 1% vs. Non-Buffered 1% Lidocaine

NCT03127943
View directory record Official record
Conditions
Anesthesia, Local
Interventions
Lidocaine
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 30 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Oct 22, 2026, 9:32 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19

NCT04343651
View directory record Official record
Conditions
Coronavirus Disease 2019
Interventions
Placebo, Leronlimab (700mg)
Drug
Lead sponsor
CytoDyn, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
12
States / cities
Los Angeles, California • Palm Springs, California • Rancho Mirage, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Oct 22, 2026, 9:32 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Th1 Response to Influenza: Aging and Vaccine Efficacy

NCT00396305
View directory record Official record
Conditions
Influenza
Interventions
Placebo, Trivalent Inactivated Influenza
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
21 Years and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Oct 22, 2026, 9:32 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

MVA-BN-RSV Vaccine Trial

NCT05238025
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
MVA-BN-RSV vaccine, Tris Buffered Saline (TBS)
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
60 Years and older
Enrollment
20,419 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
105
States / cities
Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 86 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Oct 22, 2026, 9:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Chimpanzee Adenovirus and Self-Amplifying mRNA Prime-Boost Prophylactic Vaccines Against SARS-CoV-2 in Healthy Adults

NCT04776317
View directory record Official record
Conditions
COVID-19
Interventions
ChAdV68-S, ChAdV68-S-TCE, SAM-LNP-S, SAM-LNP-S-TCE, Sodium Chloride, 0.9%
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
4
States / cities
Decatur, Georgia • St Louis, Missouri • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 22, 2026, 9:32 PM EDT
Completed Phase 1 Interventional

Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor

NCT01171469
View directory record Official record
Conditions
Brain Tumor, Glioblastoma, Medulloblastoma, Ependymoma, Anaplastic Astrocytoma
Interventions
Dendritic Cells, Imiquimod
Biological · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Not listed
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 2, 2017 · Synced Oct 22, 2026, 9:32 PM EDT
Completed Phase 2 Interventional Results available

Avoiding Treatment in the Hospital With Furoscix for the Management of Congestion in Heart Failure - A Pilot Study

NCT04593823
View directory record Official record
Conditions
Heart Failure
Interventions
Furoscix Infusor
Combination Product
Lead sponsor
scPharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
18
States / cities
Fairhope, Alabama • Huntsville, Alabama • Hartford, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 22, 2026, 9:32 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area in Subjects 65 to 75 Years of Age

NCT02123134
View directory record Official record
Conditions
Moderate to Severe Convexity of Submental Fat, Safety, Efficacy
Interventions
ATX-101, Placebo
Drug
Lead sponsor
Kythera Biopharmaceuticals
Industry
Eligibility
65 Years to 75 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
6
States / cities
Birmingham, Alabama • Los Angeles, California • Bradenton, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 22, 2026, 9:32 PM EDT
Recruiting Phase 2Phase 3 Interventional

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

NCT03970447
View directory record Official record
Conditions
Glioblastoma
Interventions
Temozolomide, Lomustine, Regorafenib, Radiation, Paxalisib, VAL-083, VT1021, Troriluzole, ADI-PEG 20, AZD1390, Tinostamustine
Drug · Radiation · Biological
Lead sponsor
Global Coalition for Adaptive Research
Other
Eligibility
18 Years and older
Enrollment
2,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
42
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 22, 2026, 9:32 PM EDT